The Food and Drug Administration on Tuesday approved a new, extended-release form of the HIV nucleoside reverse transcriptase inhibitor Zerit (d4T), which will be marketed as Zerit XR by drugmaker Bristol-Myers Squibb. The new formulation can be taken just once a day. Data from clinical trials of the medication show that it is as effective as the standard twice-daily dosing of d4T and that reducing the pill burden may help people with HIV better stick to their anti-HIV drug regimens.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes
These are some of his worst comments about LGBTQ+ people made by Charlie Kirk.